Table 5.
Numbers of patients in the ILULU-TB cohort allocated to train and test sets, for novel biosignature discovery.
| Site | Clinical group | Train (70%) | Test (30%) | TOTAL |
|---|---|---|---|---|
| Karonga | TB, HIV– | 29 | 3 | 32 |
| TB, HIV+ | 14 | 17 | 31 | |
| OD, HIV– | 11 | 20 | 31 | |
| OD, HIV+ | 24 | 4 | 28 | |
| Cape Town | TB, HIV– | 21 | 9 | 30 |
| TB, HIV+ | 21 | 8 | 29 | |
| OD, HIV– | 27 | 4 | 31 | |
| OD, HIV+ | 27 | 10 | 37 | |
| TOTAL | 174 | 75 | 249 |
Numbers in each of the clinical subgroups and at each study site are shown. Patients were allocated to train or test set at random. Only those patients with results for all 22 proteins were included.